⚠️ JAN 12 – FEB 6 CYBERATTACK: ALL ORDERS REFUNDED • DO NOT PURCHASE UNTIL FURTHER NOTICE • CONTACT support@anubis.estate FOR REFUND STATUS
Investigational new drugMitochondrial Peptide

Compound 61606

Formula Pending

Molecular Mass
N/A
CAS Registry
AUTO-061606
Risk Class
MODERATE
Last Audit
May 3, 2108

Research Abstract

Mitochondrial Peptide candidate engineered for cognitive resilience initiatives with automated dossier coverage.

Compound 61606 is a mitochondrial peptide asset inside mitochondrial peptide innovation track initiatives, optimized for cognitive resilience and neuroprotection.

The dossier currently sits in investigational new drug with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.

Supply records cite CAS AUTO-061606 with updates logged 2108-05-03.

Acquisition Protocol

Authorized research personnel may request deployment of this compound for laboratory analysis.

Primary Vectors

Cognitive resilienceNeuroprotection

Nomenclature

CX-61606Mitochondrial Peptide Program 61606

Reference Material

  1. [1] Anubis Compound Registry • CAS AUTO-061606
  2. [2] Operations Pulse • Mitochondrial Peptide innovation track
  3. [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61606